SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL
Jennifer L. Crombie(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Inhye E. Ahn(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Celeste Carey(Dana-Farber Cancer Institute), Samantha Normilus(Dana-Farber Cancer Institute), Yue Ren(Dana-Farber Cancer Institute), Mari Kniezewski(Dana-Farber Cancer Institute), Philippe Armand(Dana-Farber Cancer Institute), Shantal Solomon(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University)
Cited by 0
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890